Ambrisentan
Orphan DrugFDA Approved
Contents
Description
Ambrisentan is a selective endothelin type A receptor antagonist indicated for pulmonary arterial hypertension. It improves exercise capacity and delays clinical worsening in PAH patients. It has a more favorable hepatotoxicity profile compared to non-selective endothelin receptor antagonists.
Indications & Therapeutic Use
pulmonary arterial hypertension, WHO Group 1 pulmonary hypertension
Linked Diseases:
pulmonary hypertension
D006976
Global Availability (7 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Ambrisentan — GNH India
118 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Ambicipen
EU
Ambrican 5
5mgtabletIndia
Ambripuren
EU
Ambrisentan
EU
Ambrisentan "sandoz"
EU
Ambrisentan Abz
EU
Ambrisentan Accord
EU
Ambrisentán Alembic
EU
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Ambrisentan
| Generic Name | ambrisentan |
| Brands | 1 brand available |
| Active Ingredient | ambrisentan |
| Drug Class | pulmonary arterial hypertension |
| Manufacturer | Gilead Sciences |
| Dosage Forms | oral tablet 5mg, 10mg |
| Medical Code | C02KX02 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 10 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00091559 |
| Countries | 7 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations8 Validated Nodes